Back to homepage

Haematology and Oncology

Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report

Authors: Sonia Brugnara MD, Mariacristina Sicher MD, Elena Maria Bonandini MD, Mattia Barbareschi MD, Carlo Renè Girardelli MD, Orazio Caffo MD

This case study covers a patient who received dabrafenib and trametinib and developed vitiligo-like depigmentation after treatment cessation.

More▸

Drug therapy for double-hit lymphoma

Authors: Vania Phuoc MD, Jose Sandoval-Sus MD, Julio C Chavez MD, MS

This review discusses the role of hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy in DHL, as well as the role of potential novel agents such as BCL2 inhibitors, checkpoint inhibitors, bromodomain and extraterminal (BET) family inhibitors, Pi3K inhibitors, and others.

More▸

Neonatal pharmacology and clinical implications

Authors: Antonio Ruggiero MD, Anna Ariano MD, Silvia Triarico MD, Michele Antonio Capozza MD, Pietro Ferrara MD, Giorgio Attinà MD

This review article analyses the main pharmacokinetic aspects (ADME) that exist during the neonatal period and offers a description of the physiological background for variability in pharmacological dosing.

More▸

Venetoclax: evidence to date and clinical potential

Authors: Luis Miguel Juárez-Salcedo MD, Viraj Desai BA, Samir Dalia MD

Thsi review article describes the mechanism of action that stands behind the efficacy of venetoclax and provides a summary of available results from clinical trials.

More▸

Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD

This review focuses on the mechanisms of action, routes of administration, and efficacy of therapies for the rare genetic disorder hereditary angioedema.

More▸